Vnitr Lek 2015, 61(Suppl 5):7-11

Epidemiologic data of hyperuricaemia prevalence in the conditions of primary care in Slovakia

Andrej Dukát1,*, Peter Sabaka1, Ján Gajdošík2, Marjan Vrbnjak1, Oliver Tlčimuka1, Peter Gavorník1, Ľudovít Gašpar1, F. Šimko3
1 II. interná klinika LF UK a UN Bratislava, Slovenská republika, prednosta doc. MUDr. Ľudovít Gašpar, CSc.
2 Neštátna ambulancia pre dospelých Nové Zámky, Slovenská republika, riaditeľ prof. MUDr. Ján Gajdošík, CSc.
3 III. interná klinika LF UK a UN Bratislava, Slovenská republika, prednosta doc. MUDr. Viliam Mojto, CSc.

Hyperuricaemia represents nowaday the new risk factor for cardiovascular diseases. Prevalence data and its treatment in our patient's population are still missing. Literature data shows, that its prevalence differs in various populations significantly from 4 % up to 40 % with race and geographical means. In the hospital population its prevalence is about 7 % and represents the important predictor of hospital mortality, e.i with heart failure. From the Framingham data relative risk was estimated of 25 % for cardiovascular diseases, coronary heart disease and all-course mortality. From the epidemiologic survey Mirror Slovakia hyperuricaemia was evaluated from the sample of 20 000 patients from the primare care physicians in order to see the picture on this newer risk factor.

Keywords: cardiovascular diseases; epidemiology; hyperuricaemia; therapy

Received: July 10, 2015; Accepted: September 30, 2015; Published: October 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dukát A, Sabaka P, Gajdošík J, Vrbnjak M, Tlčimuka O, Gavorník P, et al.. Epidemiologic data of hyperuricaemia prevalence in the conditions of primary care in Slovakia. Vnitr Lek. 2015;61(Supplementum 5):7-11.
Download citation

References

  1. Alderman MH. Podagra, uric acid, and cardiovascular disease. Circulation 2007; 116(8): 880-883. Go to original source... Go to PubMed...
  2. Culleton BF, Larson MG, Kannel WB et al. Serum uric acid and risk for cardiovascular disease and death. Ann Intern Med 1999; 131(1): 7-13. Go to original source... Go to PubMed...
  3. Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout. Arthr Res Ther 2006; 8(Suppl 1): S2. Go to original source... Go to PubMed...
  4. Ghei M, Mihailescu M, Levinson D. Pathogenesis of hyperuricemia-recent advances. Curr Rheumatol Rep 2002; 4(3): 270-274. Go to original source... Go to PubMed...
  5. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007; 116(8): 894-900. Go to original source... Go to PubMed...
  6. Feig DI, Kang DG, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359(17): 1811-1821. Erratum in N Engl J Med 2010 Jun 10; 362(23):2235. Go to original source... Go to PubMed...
  7. Kriška M (ed). Zlyhanie farmakoterapie, možnosti prevencie. SAP; Bratislava 2015. ISBN 978-80-8960733-4.
  8. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011; 63(10): 3136-3141. Go to original source... Go to PubMed...
  9. Whelton A. Hyperuricemia and hypertension. Editorial comment. Hypertension 2012; 60(3): 1112-1113. Go to original source... Go to PubMed...
  10. Špinar J, Vítovec J, Pařenica J. Hypertenze a hyperurikemie. Vnitř Lék 2005; 51(1): 82-86.
  11. Loeffler LF, Navas-Acien A, Brady TM et al. Uric acid level and elevated blood pressure in US adolescents: National Health and Nutrition Examination Survey, 1999-2006. Hypertension 2012; 59(4): 811-817. Go to original source... Go to PubMed...
  12. Tangri N, Weiner DE. Uric acid, CKD, and cardiovascular disease: confounders, culprits and circles. Am J Kidn Dis 2010; 56(2): 247-250. Go to original source... Go to PubMed...
  13. Málek F, Ošťádal P, Pařenica J et al. Uric acid, allopuinol therapy, and mortality in patients with acute heart failure - results of the Acute Heart Failure Database registry. J Crit Care 2012; 27(6): 737. e11-24. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jcrc.2012.03.011>. Go to original source... Go to PubMed...
  14. Linhart A, Rob D. Význam kyseliny močové a terapie alopurinolem v ovlivnění kardiovaskulárních onemocnění. Vnitř Lék 2015; 61(5): 421-430. Go to PubMed...
  15. Choi HK, Curhan G. Independent Impact of Gout on Mortality and Risk for Coronary Heart Disease. Circulation 2007; 116(8): 894-900. Go to original source... Go to PubMed...
  16. Keenan T, Blaha MJ, Nasir K et al. Relation of uric acid to serum levels of high-sensitivity CRP, triglycerides, and HDL-C to hepatic stenosis. Am J Cardiol 2012; 110(12): 1787-1792. Go to original source... Go to PubMed...
  17. Choi HK, Soriano LC, Zhang Y et al. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ 2012; 344:d8190. Dostupné z DOI: <http://doi:10.1136/bmj.d8190>. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.